Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced nonsmall cell lung cancer (LA-NSCLC): A population-based multicenter study

Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: 4f0324a96922b0e2a4f327c72721996e530c9ce6
First added on: Feb 16, 2025